

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 as amended from time to time (the “**U.S. Securities Act**”) or securities law of any state or other jurisdiction of the United States. The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws, or (1) solely to qualified institutional buyers as defined in Rule 144A under the U.S. Securities Act pursuant to an exemption from registration under the U.S. Securities Act and (2) outside the United States unless in compliance with Regulation S under the U.S. Securities Act. There will be no public offer of securities in the United States.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the prospectus dated June 29, 2023 (the “**Prospectus**”) issued by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “**Company**”) for detailed information about the Global Offering described below before deciding whether or not to invest in the H Shares thereby being offered. The Company has not been and will not be registered under the U.S. Investment Company Act of 1940, as amended.

Unless otherwise defined in this announcement, capitalized terms used herein shall have the same meanings as those defined in the Prospectus.

In connection with the Global Offering, Goldman Sachs (Asia) L.L.C. as stabilization manager (the “**Stabilization Manager**”) (or its affiliates or any person acting for it), on behalf of the Underwriters, the extent permitted by the applicable laws and regulatory requirements of Hong Kong or elsewhere, may over-allocate or effect transactions with a view to stabilizing or supporting the market price of the H Shares at such price, in such amounts and in such manners as the Stabilization Manager, its affiliates or any person acting for it may determine and at a level higher than that which might otherwise prevail for a limited period after the Listing Date. However, there is no obligation on the Stabilization Manager (or its affiliates or any person acting for it) to conduct any such stabilizing action. Such stabilizing action, if taken, (a) will be conducted at the absolute discretion of the Stabilization Manager (or its affiliates or any person acting for it) and in what the Stabilization Manager reasonably regards as the best interest of our Company, (b) may be discontinued at any time and (c) is required to be brought to an end within 30 days of the last day for lodging applications under the Hong Kong Public Offering (which is Thursday, August 3, 2023). Such stabilization action, if taken, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), as amended, made under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Potential investors should be aware that no stabilizing action can be taken to support the price of the H Shares for longer than the stabilization period, which will begin on the Listing Date, and is expected to expire on the 30th day after the last day for lodging applications under the Hong Kong Public Offering (which is Thursday, August 3, 2023). After this date, when no further stabilizing action may be taken, demand for the H Shares, and therefore the price of the H Shares, could fall.

Potential investors of the Offer Shares should note that the Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the paragraph headed “Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on Tuesday, July 11, 2023).



**KELUN-BIOTECH**  
**科倫博泰**

**Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.**  
**四川科倫博泰生物醫藥股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**GLOBAL OFFERING**

<b>Number of Offer Shares under the Global Offering</b>	<b>: 22,446,100 H Shares (subject to the Over-allotment Option)</b>
<b>Number of Hong Kong Offer Shares</b>	<b>: 2,244,700 H Shares (subject to reallocation)</b>
<b>Number of International Offer Shares</b>	<b>: 20,201,400 H Shares (subject to reallocation and the Over-allotment Option)</b>
<b>Maximum Offer Price</b>	<b>: HK\$72.80 per H Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and the Stock Exchange trading fee of 0.00565% (payable in full on application in Hong Kong Dollars, subject to refund)</b>
<b>Nominal Value</b>	<b>: RMB1.00 per Offer Share</b>
<b>Stock Code</b>	<b>: 6990</b>

*Joint Sponsors, Overall Coordinators, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers*

**Goldman  
Sachs**

 **CITIC SECURITIES**

*Joint Global Coordinator, Joint Bookrunner and Joint Lead Manager*



*Joint Bookrunners and Joint Lead Managers*

**ICBC**  **工銀國際**

 **交銀國際**  
BOCOM International

The Company has applied to the Listing Committee of the Stock Exchange for the listing of, and permission to deal in, the H Shares to be issued pursuant to the Global Offering (including any additional H Shares which may be issued pursuant to the exercise of the Over-allotment Option and the H Shares to be converted from the Domestic Shares). Assuming that the Hong Kong Public Offering becomes unconditional at or before 8:00 a.m. in Hong Kong on Tuesday, July 11, 2023, dealings in the H Shares on the Stock Exchange are expected to commence at 9:00 a.m. in Hong Kong on Tuesday, July 11, 2023.

## IMPORTANT NOTICE TO INVESTORS:

### FULLY ELECTRONIC APPLICATION PROCESS

We have adopted a fully electronic application process for the Hong Kong Public Offering. We will not provide printed copies of the Prospectus or printed copies of any application forms to the public in relation to the Hong Kong Public Offering.

The Prospectus is available at the website of the Hong Kong Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk) under the “*HKEXnews > New Listings > New Listing Information*” section, and our website at <http://kelun-biotech.com>. If you require a printed copy of the Prospectus, you may download and print from the website addresses above.

To apply for the Hong Kong Offer Shares, you may:

- (1) apply online via the **White Form eIPO** service at [www.eipo.com.hk](http://www.eipo.com.hk); or
- (2) apply through the **CCASS EIPO** service to electronically cause HKSCC Nominees to apply on your behalf, including by:
  - i. instructing your **broker** or **custodian** who is a CCASS Clearing Participant or a CCASS Custodian Participant to give **electronic application instructions** via CCASS terminals to apply for the Hong Kong Offer Shares on your behalf; or
  - ii. (if you are an existing **CCASS Investor Participant**) giving **electronic application instructions** through the CCASS Internet System (<https://ip.ccass.com>) or through the CCASS Phone System by calling +852 2979 7888 (using the procedures in HKSCC’s “An Operating Guide for Investor Participants” in effect from time to time). HKSCC can also input **electronic application instructions** for CCASS Investor Participants through HKSCC’s Customer Service Centre at 1/F, One & Two Exchange Square, 8 Connaught Place, Central, Hong Kong by completing an input request.

If you have any question about the application for the Hong Kong Offer Shares, you may call the enquiry hotline of our H Share Registrar and **White Form eIPO** Service Provider, **Computershare Hong Kong Investor Services Limited**, both at +852 2862 8600 on the following dates:

**Thursday, June 29, 2023 – 9:00 a.m. to 9:00 p.m.**  
**Friday, June 30, 2023 – 9:00 a.m. to 9:00 p.m.**  
**Monday, July 3, 2023 – 9:00 a.m. to 9:00 p.m.**  
**Tuesday, July 4, 2023 – 9:00 a.m. to 12:00 noon**

We will not provide any physical channels to accept any application for the Hong Kong Offer Shares by the public. The contents of the electronic version of the Prospectus are identical to the printed document as registered with the Registrar of Companies in Hong Kong pursuant to Section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong).

If you are an **intermediary, broker or agent**, please remind your customers, clients or principals, as applicable, that the Prospectus is available online at the website addresses above.

Please refer to the section headed “How to apply for Hong Kong Offer Shares” in the Prospectus for further details of the procedures through which you can apply for the Hong Kong Offer Shares electronically.

Your application through the **White Form eIPO** service and the **electronic application instructions** to HKSCC must be for a minimum of 100 Hong Kong Offer Shares and in one of the numbers set out in the table. You are required to pay the amount next to the number you select.

**Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.**  
**(HK\$72.80 per Hong Kong Offer Share)**  
**NUMBER OF HONG KONG OFFER SHARES**  
**THAT MAY BE APPLIED FOR AND PAYMENTS**

No. of Hong Kong Offer Shares applied for	Amount payable on application <i>HK\$</i>	No. of Hong Kong Offer Shares applied for	Amount payable on application <i>HK\$</i>	No. of Hong Kong Offer Shares applied for	Amount payable on application <i>HK\$</i>	No. of Hong Kong Offer Shares applied for	Amount payable on application <i>HK\$</i>
100	7,353.42	2,500	183,835.46	20,000	1,470,683.75	200,000	14,706,837.60
200	14,706.83	3,000	220,602.57	25,000	1,838,354.70	300,000	22,060,256.40
300	22,060.25	3,500	257,369.66	30,000	2,206,025.65	400,000	29,413,675.20
400	29,413.68	4,000	294,136.75	35,000	2,573,696.58	500,000	36,767,094.00
500	36,767.09	4,500	330,903.85	40,000	2,941,367.52	600,000	44,120,512.80
600	44,120.52	5,000	367,670.95	45,000	3,309,038.45	700,000	51,473,931.60
700	51,473.94	6,000	441,205.13	50,000	3,676,709.40	800,000	58,827,350.40
800	58,827.35	7,000	514,739.31	60,000	4,412,051.28	900,000	66,180,769.20
900	66,180.77	8,000	588,273.50	70,000	5,147,393.15	1,000,000	73,534,188.00
1,000	73,534.19	9,000	661,807.69	80,000	5,882,735.05	1,122,300 <sup>(1)</sup>	82,527,419.19
1,500	110,301.28	10,000	735,341.88	90,000	6,618,076.92		
2,000	147,068.38	15,000	1,103,012.82	100,000	7,353,418.80		

(1) Maximum number of Hong Kong Offer Shares you may apply for.

No application for any other number of Hong Kong Offer Shares will be considered and any such application is liable to be rejected.

## STRUCTURE OF THE GLOBAL OFFERING

The Global Offering comprises:

- the Hong Kong Public Offering of initially 2,244,700 H Shares (subject to reallocation) representing approximately 10.0% of the total number of Offer Shares initially available under the Global Offering, and
- the International Offering of initially 20,201,400 H Shares (subject to reallocation and the Over-allotment Option) representing approximately 90.0% of the total number of Offer Shares initially available under the Global Offering.

The allocation of the Offer Shares between the Hong Kong Public Offering and the International Offering will be subject to reallocation as described in the section headed “Structure of the Global Offering” in the Prospectus.

In particular, Offer Shares may be reallocated from the International Offering to the Hong Kong Public Offering to satisfy valid applications under the Hong Kong Public Offering. In accordance with Guidance Letter HKEX-GL91-18 issued by the Stock Exchange, if such reallocation is done other than pursuant to clawback mechanism as described in the section headed “Structure of the Global Offering — the Hong Kong Public Offering — Reallocation” in the Prospectus, the maximum total number of Offer Shares available under the Hong Kong Public Offering shall be 4,489,400 Offer Shares, representing approximately 20% of the total number of Offer Shares initially available under the Global Offering and the final Offer Price shall be fixed at the low-end of the indicative Offer Price range (i.e. HK\$60.60 per Offer Share) stated in the Prospectus.

In connection with the Global Offering, our Company is expected to grant the Over-allotment Option to the International Underwriters, exercisable by the Overall Coordinators. Pursuant to the Over-allotment Option, the International Underwriters will have the right, exercisable by the Overall Coordinators at any time from the Listing Date until 30 days after the last day for lodging applications under the Hong Kong Public Offering (which is Thursday, August 3, 2023), to require our Company to issue up to an aggregate of 3,366,900 additional H Shares, representing not more than 15.0% of the total number of Offer Shares initially available under the Global Offering, at the Offer Price to, cover over-allocations (if any) in the International Offering. In the event the Over-allotment Option is exercised, we will make an announcement which will be posted on the website of the Stock Exchange ([www.hkexnews.hk](http://www.hkexnews.hk)) and on our website (<http://kelun-biotech.com>), respectively.

## PRICING

The Offer Price will not be more than HK\$72.80 per Offer Share and is expected to be not less than HK\$60.60 per Offer Share, unless otherwise announced, as further explained in the section headed “Structure of the Global Offering” in the Prospectus. Applicants under the Hong Kong Public Offering must pay, on application, the maximum Offer Price of HK\$72.80 per Offer Share plus brokerage of 1.0%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.00565%, amounting to a total of HK\$7,353.42 for one board lot of 100 H Shares, subject to refund if the Offer Price as finally determined is less than HK\$72.80 per Offer Share. **Prospective investors should be aware that the Offer Price to be determined on the Price Determination Date may be, but is not expected to be, lower than the minimum Offer Price stated in the Prospectus.**

## EXPECTED TIMETABLE

Hong Kong Public Offering commences . . . . . 9:00 a.m. on  
Thursday, June 29, 2023

Latest time to complete electronic applications under  
**White Form eIPO** service through the designated  
website [www.eipo.com.hk](http://www.eipo.com.hk) . . . . . 11:30 a.m. on  
Tuesday, July 4, 2023

Application lists of the Hong Kong Public Offering open . . . . . 11:45 a.m. on  
Tuesday, July 4, 2023

Latest time to give **electronic application instructions** to HKSCC . . . . . 12:00 noon on  
Tuesday, July 4, 2023

Latest time to complete payment of **White Form eIPO**  
applications by effecting Internet banking transfer(s) or  
PPS payment transfer(s) . . . . . 12:00 noon on  
Tuesday, July 4, 2023

If you are instructing your **broker** or **custodian** who is a CCASS Clearing Participant or a CCASS Custodian Participant to give **electronic application instructions** via CCASS terminals to apply for the Hong Kong Offer Shares on your behalf, you are advised to contact your **broker** or **custodian** for the latest time for giving such instructions which may be different from the latest time as stated above.

Application lists of the Hong Kong Public Offering close . . . . . 12:00 noon on  
Tuesday, July 4, 2023

Expected Price Determination Date . . . . . Tuesday, July 4, 2023

Announcement of the Offer Price, an indication of the level of interest in the International Offering, the level of applications in the Hong Kong Offering and the basis of allocation of the Hong Kong Offer Shares to be published on the websites of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk) and our Company at <http://kelun-biotech.com> on or before . . . . . Monday, July 10, 2023

Announcement of results of allocations in the Hong Kong Public Offering (including successful applicants' identification document numbers, where appropriate) to be available through a variety of channels (as described in the section headed "How to Apply for Hong Kong Offer Shares — 11. Publication of Results" in this prospectus), including:

- in the announcement to be posted on our website at <http://kelun-biotech.com> and the Stock Exchange's website at [www.hkexnews.hk](http://www.hkexnews.hk), respectively . . . . . Monday, July 10, 2023



- Results of allocations in the Hong Kong Public Offering to be available at [www. iporesults.com.hk](http://www.iporesults.com.hk) (alternatively: English <https://www.eipo.com.hk/en/Allotment>; Chinese <https://www.eipo.com.hk/zh-hk/Allotment>) with a “search by ID” function from . . . . . 8:00 a.m. on Monday, July 10, 2023 to 12:00 midnight on Sunday, July 16, 2023
- from the allocation results telephone enquiry by calling +852 2862 8555 between 9:00 a.m. and 6:00 p.m. on . . . . . Monday, July 10, 2023, Tuesday, July 11, 2023, Wednesday, July 12, 2023 and Thursday, July 13, 2023

**White Form** e-Refund payment instructions/refund checks in respect of wholly or partially successful applications if the final Offer Price is less than the maximum Offer Price per Offer Share initially paid on application (if applicable) or wholly or partially unsuccessful applications to be dispatched/collected on or before . . . . . Monday, July 10, 2023

Dispatch/collection of H Share certificates or deposit of H Share certificates into CCASS in respect of wholly or partially successful application under the Hong Kong Public Offering on or before. . . . . Monday, July 10, 2023

Dealings in H Shares on the Stock Exchange to commence at 9:00 a.m. on. . . . . Tuesday, July 11, 2023

*Note:*

(1) All dates and times refer to Hong Kong local time and date, except as otherwise stated.

**SETTLEMENT**

Subject to the granting of the listing of, and permission to deal in, the H Shares on the Stock Exchange and our compliance with the stock admission requirements of HKSCC, the H Shares will be accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS with effect from the Listing Date or any other date as determined by HKSCC. Settlement of transactions between Exchange Participants (as defined in the Listing Rules) is required to take place in CCASS on the second settlement day after any trading day. All activities under CCASS are subject to the General Rules of CCASS and CCASS Operational Procedures in effect from time to time. Investors should seek the advice of their stockbroker or other professional advisor for details of the settlement arrangements as such arrangements may affect their rights and interests. All necessary arrangements have been made enabling the H Shares to be admitted into CCASS.

## ELECTRONIC APPLICATION CHANNELS

### White Form eIPO service

You may submit your application to the **White Form eIPO** Service Provider at [www.eipo.com.hk](http://www.eipo.com.hk) (24 hours daily, except on the last application day) from 9:00 a.m. on Thursday, June 29, 2023 until 11:30 a.m. on Tuesday, July 4, 2023 and the latest time for completing full payment of application monies in respect of such applications will be 12:00 noon on Tuesday, July 4, 2023 or such later time under the paragraph headed “– 10. Effect of Bad Weather and/or Extreme Conditions on the Opening and Closing of the Application Lists” in this section.

### CCASS EIPO service <sup>(Note)</sup>

CCASS Clearing/Custodian Participants can input **electronic application instructions** at the following times on the following dates:

<b>Thursday, June 29, 2023</b>	<b>– 9:00 a.m. to 8:30 p.m.</b>
<b>Friday, June 30, 2023</b>	<b>– 8:00 a.m. to 8:30 p.m.</b>
<b>Monday, July 3, 2023</b>	<b>– 8:00 a.m. to 8:30 p.m.</b>
<b>Tuesday, July 4, 2023</b>	<b>– 8:00 a.m. to 12:00 noon</b>

CCASS Investor Participants can input **electronic application instructions** from 9:00 a.m. on Thursday, June 29, 2023 until 12:00 noon on Tuesday, July 4, 2023 (24 hours daily, except on Tuesday, July 4, 2023, the last day for applications).

The latest time for inputting your **electronic application instructions** will be 12:00 noon on Tuesday, July 4, 2023, the last day for applications or such later time as described in “– 10. Effect of Bad Weather and/or Extreme Conditions on the Opening and Closing of the Application Lists” in the Prospectus.

*Note:* The times in this sub-section are subject to change as HKSCC may determine from time to time with prior notification to CCASS Clearing/Custodian Participants and/or CCASS Investor Participants.

All application monies will be held in separate bank account(s) with the receiving banks or other bank(s) in Hong Kong licensed under the Banking Ordinance (Chapter 155 of the Laws of Hong Kong) after the closing of the application lists and the refund monies, if any, will be returned to the applicants without interest on or before Monday, July 10, 2023. Investors should be aware that the dealings in the H Shares on the Stock Exchange are expected to commence on Tuesday, July 11, 2023.

Please refer to the sections headed “Structure of the Global Offering” and “How to Apply for Hong Kong Offer Shares” of the Prospectus for details of the conditions and procedures of the Hong Kong Public Offering.

**Application for the Hong Kong Offer Shares will only be considered on the basis of the terms and conditions set out in the Prospectus, and on the designated website at [www.eipo.com.hk](http://www.eipo.com.hk) for the White Form eIPO service.**



## PUBLICATION OF RESULTS

The Company expects to announce the Offer Price, the level of indications of interest in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of allocation of the Hong Kong Offer Shares on Monday, July 10, 2023 on the Company's website at <http://kelun-biotech.com> and the website of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk).

The results of allocations and the Hong Kong identity card/passport/Hong Kong business registration/certificate of incorporation numbers of successful applicants under the Hong Kong Public Offering will be available through a variety of channels at the times and date and in the manner specified in the section headed "How to Apply for Hong Kong Offer Shares — 11. Publication of Results" in the Prospectus.

If an application is rejected, not accepted or accepted in part only, or if the Offer Price as finally determined is less than the maximum Offer Price of HK\$72.80 per Offer Share (excluding brokerage, SFC transaction levy, AFRC transaction levy and Stock Exchange trading fee payable thereon) paid on application, or if the conditions of the Global Offering as set out in the section headed "Structure of the Global Offering — Conditions of the Global Offering" in the Prospectus are not satisfied or if any application is revoked, the application monies, or the appropriate portion thereof, together with the related brokerage, SFC transaction levy, AFRC transaction levy and Stock Exchange trading fee, will be refunded, without interest.

No temporary document of title will be issued in respect of the Offer Shares. No receipt will be issued for sums paid on application. H Share certificates will only become valid at 8:00 a.m. on Tuesday, July 11, 2023, provided that the Global Offering has become unconditional in all respects at or before that time. Investors who trade H Shares on the basis of publicly available allocation details or prior to the receipt of H Share certificates or prior to the H Share certificates becoming valid do so entirely at their own risk. Assuming that the Hong Kong Public Offering becomes unconditional at or before 8:00 a.m. in Hong Kong on Tuesday, July 11, 2023, it is expected that dealings in the H Shares on the Stock Exchange will commence at 9:00 a.m. on Tuesday, July 11, 2023. The H Shares will be traded in board lots of 100 H Shares each and the stock code of the H Shares will be 6990.

This announcement is available for viewing on the website of the Company at <http://kelun-biotech.com> and the website of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk).

By order of the Board  
**Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.**  
**LIU Gexin**  
*Chairman of the Board and Non-executive Director*

Hong Kong, Thursday, June 29, 2023

*As at the date of this announcement, the Board of Directors of the Company comprises Mr. LIU Gexin as the chairman of the Board and non-executive Director, Dr. GE Junyou and Dr. WANG Jingyi as executive Directors, Mr. LIU Sichuan, Mr. FENG Hao, Mr. ZENG Xuebo and Mr. LI Dongfang as non-executive Directors, and Dr. ZHENG Qiang, Dr. TU Wenwi, Dr. JIN Jingping, and Dr. LI Yuedong as independent non-executive Directors.*